These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1717981)

  • 1. Characterization of a neu/c-erbB-2 protein-specific activating factor.
    Dobashi K; Davis JG; Mikami Y; Freeman JK; Hamuro J; Greene MI
    Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8582-6. PubMed ID: 1717981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium.
    Davis JG; Hamuro J; Shim CY; Samanta A; Greene MI; Dobashi K
    Biochem Biophys Res Commun; 1991 Sep; 179(3):1536-42. PubMed ID: 1681805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the normal and oncogenic forms of the neu tyrosine kinase, and the corresponding forms of an immunoglobulin E receptor/neu tyrosine kinase fusion protein, on Xenopus oocyte maturation.
    Narasimhan V; Hamill O; Cerione RA
    FEBS Lett; 1992 Jun; 303(2-3):164-8. PubMed ID: 1351469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene.
    Yarden Y; Weinberg RA
    Proc Natl Acad Sci U S A; 1989 May; 86(9):3179-83. PubMed ID: 2470093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases.
    Quian XL; Decker SJ; Greene MI
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1330-4. PubMed ID: 1346931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
    Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
    J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand and p185c-neu density govern receptor interactions and tyrosine kinase activation.
    Samanta A; LeVea CM; Dougall WC; Qian X; Greene MI
    Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1711-5. PubMed ID: 7907421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages.
    Tarakhovsky A; Zaichuk T; Prassolov V; Butenko ZA
    Oncogene; 1991 Dec; 6(12):2187-96. PubMed ID: 1685016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
    Zhang L; Chang CJ; Bacus SS; Hung MC
    Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
    Muthuswamy SK; Muller WJ
    Oncogene; 1995 Nov; 11(9):1801-10. PubMed ID: 7478608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor.
    Muthuswamy SK; Muller WJ
    Oncogene; 1995 Jul; 11(2):271-9. PubMed ID: 7542762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
    Wildenhain Y; Pawson T; Blackstein ME; Andrulis IL
    Oncogene; 1990 Jun; 5(6):879-83. PubMed ID: 1694290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB; Kokai Y; Wada T; Cohen JA; Williams WV; Greene MI
    Oncogene; 1989 Oct; 4(10):1175-83. PubMed ID: 2571965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor.
    Brown VI; Shah N; Smith R; Hellman M; Jarett L; Mikami Y; Cohen E; Qian X; Greene MI
    DNA Cell Biol; 1994 Feb; 13(2):193-209. PubMed ID: 7910024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2/neu proto-oncogene product is induced by hyperosmotic shock.
    King CR; Borrello I; Porter L; Comoglio P; Schlessinger J
    Oncogene; 1989 Jan; 4(1):13-8. PubMed ID: 2464783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of oncogenic and cellular p185 by serine/threonine kinases.
    Dobashi K; Weiner DB; Greene MI
    DNA; 1989 Dec; 8(10):723-32. PubMed ID: 2575488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
    Ethier SP; Kokeny KE; Ridings JW; Dilts CA
    Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the neu oncogene product in cell transformation and normal development.
    Kokai Y; Wada T; Myers JN; Brown VI; Dobashi K; Cohen J; Hamuro J; Weiner DB; Greene MI
    Princess Takamatsu Symp; 1988; 19():45-57. PubMed ID: 2908355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
    Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
    Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation.
    Qian X; LeVea CM; Freeman JK; Dougall WC; Greene MI
    Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1500-4. PubMed ID: 7509075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.